Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib, Lenalidomide, and Rituximab (aR2) in Previously Untreated Follicular Lymphoma
NCT04404088Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2020
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
A Phase 2 trial of acalabrutinib tablet (Variant 1) in follicular lymphoma (FL), sponsored by University of Texas MD Anderson Cancer Center. Started Jul 2020; status: recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT04404088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04404088.